Carafate Suspension
Product Images NDC 58914-170

2 FDA label images from Allergan, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Carafate (NDC 58914-170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carafate Oral Suspension Contains Sucralfate And Sucralfate Is An α-d-glucopyranoside, β-d- Fructofuranosyl-, Octakis-(hydrogen Sulfate), Aluminum Complex. (Carafate Oral Suspension 01)

Carafate Oral Suspension Contains Sucralfate And Sucralfate Is An α-d-glucopyranoside, β-d- Fructofuranosyl-, Octakis-(hydrogen Sulfate), Aluminum Complex. (Carafate Oral Suspension 01)
Chemical structure of sucralfate showing its polymeric complex with aluminum hydroxide and water molecules, including notation for R groups as SO3Al(OH)2.*
FDA Label Image

Principal Display Panelndc 58914-170-14carafate®(sucralfate)oralsuspension1g/ 10mlone 420 mL Bottlerx Only (Carafate Oral Suspension 02)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.